2 results match your criteria: "3Division of Clinical Pathology[Affiliation]"
Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF mutated melanoma cells in vitro.
Cancer Cell Int
August 2019
1Division of Surgical Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126 Pisa, Italy.
Background: Neoplastic cells promote a hypercoagulable state by the expression of cell surface proteins, such as tissue factor. In BRAF mutated melanoma patients upon BRAF inhibitors, a hypercoagulable state correlates with prognosis, while a down-regulation of the hemostatic parameters is observed in patients responders as compared to non responders. The present study was intended to better clarify the strict relationship between coagulation mediators and target therapy in melanoma.
View Article and Find Full Text PDFMesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Anticancer Res
June 2013
Division of Histopathology and Cytopathology, 2Division of Pneumology, 3Division of Clinical Pathology, Azienda Sanitaria Locale n˚ 5, La Spezia, Italy.
Background/aim: Soluble mesothelin-related peptide (SMRP) is regarded as a biomarker of malignant pleural mesothelioma (MPM). Herein, we compared the diagnostic performances of SMRP in matched pleural effusion (PE-SMRP) and serum (S-SMRP).
Materials And Methods: Diagnosis on pleural biopsies was performed for all patients including 43 with MPM, 23 with non-MPM pleural metastases (MTS) and 36 with benign (BNG) pleural diseases.